#China #Qingdao #Global Sales #Laboratory Equipment #Haier Biomedical

Haier Biomedical Achieves Top Rankings in Global Lab Equipment

Haier Biomedical, a leading player in the life sciences laboratory equipment sector, has recently secured two top spots in the Global Life Science Lab Equipment Report by Euromonitor International. This recognition marks a significant milestone for the company, as it emerges as the foremost Chinese brand in global sales and international markets for laboratory equipment specifically designed for life sciences.

According to the 2025 data from Euromonitor, Haier Biomedical's impressive performance showcases its successful three-phase global expansion, which has led to a compound annual growth rate (CAGR) exceeding 20%. This achievement not only illustrates the brand's competitive edge but also highlights its ability to contend with well-established international manufacturers in a fiercely competitive market.

The importance of these rankings cannot be overstated, particularly for international partners considering collaboration with the brand. In industries where reliability, regulatory compliance, and ongoing support are critical factors influencing purchasing decisions, an independent verification of market leadership provides additional reassurance to institutions in the process of evaluating potential suppliers.

The company's global growth trajectory began with focused initiatives, collaborating with prominent organizations such as UNICEF and WHO to address specific unmet needs within the industry. By establishing a leadership position in solar-powered vaccine storage, Haier Biomedical created a solid foundation for further expansion. Currently, the company has successfully increased its distribution network to 160 countries, working through over 800 active distributors to ensure widespread availability of its products.

At this stage of development, Haier Biomedical is directing efforts towards building comprehensive operational capabilities in key regions. This includes local warehousing, sales, marketing, and product planning, as well as research and development (R&D). With R&D centers located in the UK, Italy, and Japan, the company specializes in various product lines, such as centrifuges, cold chain storage solutions, automated storage systems, incubators, and biosafety cabinets.

In both the UK and continental Europe, dedicated product specialists in automation and centrifuge technology are on hand to provide on-site support for Good Manufacturing Practice (GMP) compliance, air safety, and sample purification. Such measures position Haier Biomedical as a workflow partner for laboratories, where service standards established in the US and the UK are replicated in the EU, Southeast Asia, and South Asia.

In the first quarter of 2026, Haier Biomedical reported revenue increases of over 50% in countries like Germany, Australia, and Canada. Meanwhile, Eastern Europe, South Asia, and Brazil each experienced growth rates of over 100% year-on-year, with both centrifuges and incubators seeing volumes double. The company's presence in the pharmaceutical sector leverages its partnerships with several leading pharmaceutical firms across key nations such as Switzerland, Germany, Denmark, Italy, Singapore, the USA, Israel, and India.

Moreover, Haier Biomedical's 'Ultra Energy' series holds the top eight positions in the Energy Star ratings for its category in the United States, establishing it as the best-selling line within that segment. Looking to the future, the company plans to strengthen its investments in localization while expanding its product portfolio, aiming to further enhance the efficiency and sustainability of biopharmaceutical and life sciences laboratories. This aligns with Haier Biomedical's vision of being the global leader in providing integrated tools for life sciences and smart productivity platforms.

For further insights and information about their offerings, visit Haier Biomedical.